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ABSTRACT
Background: Bronchial asthma is a chronic inflammatory disease that has a severe impact on health world-
wide.
Methods: A survey of 10,771 patients with bronchial asthma in the Tama region, Tokyo was conducted for 5
years to examine treatment and quality of life (QOL). Subjects were patients aged 16 years and their physi-
cians who replied to a questionnaire sent in November from 2002 to 2006. Symptoms of bronchial asthma, vis-
its to an emergency room, use of drugs, and severity of asthma were investigated.
Results: Asthmatic symptoms improved over the 5 years, with a reduction in the number of emergency room
visits. Since inhaled corticosteroids (ICS) were used by >80% of patients in 2002, we suspected that increased
use of concomitant leukotriene receptor antagonists (LTRA) and long-acting β2 agonists (LABA) might have
contributed to these findings. The effects of these drugs were compared between ICS + LTRA (n = 45) and
ICS + LABA (n = 54) groups of patients. There was no significant difference in the ICS dose between these
groups. In the ICS + LABA group, 18.5% and 22.2% of patients visited an emergency room before and after in-
itiation of combination therapy, respectively, with no statistically significant difference. In contrast, the rate of
emergency room visits in the ICS + LTRA group decreased from 24.4% to 6.6% after addition of LTRA.
Conclusions: These results suggest that the frequency of visits to an emergency room was decreased by
complementing the anti-inflammatory effect of ICS with further treatment of inflammation, particularly with
LTRA.
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INTRODUCTION
Bronchial asthma is a chronic inflammatory disease
of the airways1 that is commonly treated with anti-
inflammatory agents such as inhaled corticosteroids
(ICS) and leukotriene receptor antagonists (LTRA).
Use of these drugs has decreased the rates of hospi-
talization and death due to asthma attacks. In Japan,
more than 6,000 people died from asthma in the
1990s, whereas the total number of deaths in the cur-
rent century was less than 2,500 by 2008.2 Asphyxi-
ation caused by a severe attack is a major cause of
death in asthma, and most cases involve sudden
death.3 The pathology of asthma includes airway in-
flammation, which leads to airway obstruction due to
smooth muscle contraction, mucosal swelling, in-
creased airway secretion, and airway wall remodel-
ing.4 Autopsies show that patients with asthma who
died suddenly had chronic inflammation in the air-
ways and that death was due to aggravation of inflam-
mation.3 Therefore, inappropriate daily management
of asthma can induce severe attacks that can result in
death, which indicates the importance of long-term
asthma control with treatment against airway inflam-
mation.5
In Finland, a 10-year comprehensive program has
decreased the hospitalization period and deaths due
to asthma, despite an increase in the number of pa-
tients with asthma. This program has also contrib-
uted to reduction of healthcare costs. The main strat-
egy is to initiate treatment with ICS at an early stage.
As a result, ICS are prescribed for 80% of patients in
Finland,6 in contrast to 15% in Japan in 2005.7 There-
fore, it is important for the government, allergists and
primary care physicians in Japan to cooperate with
each other in promoting standard treatment with ICS
to decrease mortality due to asthma. Furthermore,
elderly patients (aged60 years) accounted for 90% of
deaths due to asthma in Japan,8 and this percentage
has increased year by year. This makes it important
to improve asthma treatment for elderly patients in
order to decrease mortality due to asthma. Elderly
patients in Japan often have age-associated respira-
tory dysfunction, complicated chronic obstructive pul-
monary disease (COPD) and poor adherence to inha-
lants, all of which may reduce ICS distribution to pe-
ripheral tissues and result in incomplete treatment of
inflammation.
To examine trends in asthma treatment, local hos-
pitals and primary care physicians in Tama region,
130 facilities in total, established the Tama Research
Group on QOL in Bronchial Asthma. We conducted a
survey in a total of 10,771 bronchial asthma patients
over 5 years from 2002 to 2006 using a questionnaire
prepared by the Tama Research Group to evaluate
the conditions and QOL of patients with asthma.
Tama region is located in the western part of Tokyo
and consists of commercial, industrial and agricul-
tural zones. It has an area of 1,169.49 km2 and a popu-
lation of approximately 4 million. Based on this sur-
vey, we analyzed whether an increase in ICS use im-
proved asthma control in the region and whether ad-
dition of LABA or LTRA to ICS changed the QOL of
asthma patients.
METHODS
The survey was conducted each November from 2002
to 2006. The subjects were outpatients diagnosed
with bronchial asthma in hospitals, respiratory clinics
and general clinics in Tama region. All the subjects
gave informed consent. This study was approved by
the ethics committee of the Tama Research Group to
evaluate the conditions and QOL of patients with
asthma.
The questionnaire used in the survey was prepared
by the Tama Research Group on QOL in Bronchial
Asthma, consisting of questions for patients and phy-
sicians to define management and severity of bron-
chial asthma and self-assessment by patients, based
on the Asthma Prevention and Management Guide-
lines 1998 (JGL 1998) of the Japanese Society of Al-
lergology9 (Table 1). The questionnaire included 13
questions for patients on current subjective symp-
toms, incidence of symptoms, time of symptom ap-
pearance, sleep, effects on daily life, compliance with
drug regimens, and visits to an emergency room. The
questionnaire also included questions for physicians
regarding treatment and severity. Based on the
Asthma Prevention and Management Guidelines
1998 (JGL1998) of the Japanese Society of Allergol-
ogy,9 severity of asthma was classified into Steps 1 to
4, which are also valid in the latest version of the
Asthma Prevention and Management Guidelines
2009.10 The ICS dosage indicated by a physician in
the questionnaire was converted to the amount of be-
clomethasone dipropionate (BDP) in the dosage.
Based on the definition of the Global Initiative for
Asthma (GINA) control level11 (Table 2), patients
who answered “No” to questions 3, 5, 6 and 12 in the
Tama original questionnaire (which were consistent
with the items for the GINA control level) were con-
sidered to have asthma that was controlled.
To determine which medication would have addi-
tional effects to those of ICS on decreasing the num-
ber of emergency visits, we selected 54 cases that
utilized LABA in addition to ICS (ICS + LABA group)
and 45 cases with LTRA in addition to ICS (ICS +
LTRA group). We checked their effects one year after
initiation of LABA or LTRA, focusing on ICS dose and
emergency visits. Patient background factors with a
possible association with visits to an emergency room
due to an asthma attack were also analyzed.
Statistical analysis was performed using a chi-
square test for the asthma control level. A Wilcoxon
test was used to compare frequencies of visits to an
emergency room before and after initiation of combi-
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Fig.　1　Background of 10,771 asthma patients surveyed from 2002 to 2006. Severity distribution by (a) 
sex, (b) age and (c) year.
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Table　2　Levels of asthma control
Characteristic Controlled Partly Controlled Uncontrolled
Daytime symptoms None (twice or less/week) More than twice/week Three or more fea-
tures of partly con-
trolled asthma pres-
ent in any week
Limitation of activities None Any
Nocturnal symptoms/awakening None Any
Need for reliever/rescue treatment None (twice or less/week) More than twice/week
Lung function (PEF or FEV1) Normal <80% predicted or personal best
Exacerbations None One or more/year One in any week
Patients who answered “No” to 4 questions in the Tama original questionnaire that were consistent with the items on the GINA control
scale were considered to have asthma that was “completely controlled.”
nation therapy. Multivariate analysis was used to
identify background factors with a significant associa-
tion with visits to an emergency room due to an
asthma attack. A p value of <0.05 was considered to
be significant in all analyses.
RESULTS
The number of respondents to the questionnaire on
QOL in Bronchial Asthma were 1,591 in 2002, 2,407
in 2003, 1,751 in 2004, 1,664 in 2005 and 2,358 in
2006, giving a total of 10,771 respondents for the 5
years. Twenty-three patients repeatedly participated
in the survey every year for five years; 53 patients for
consecutive four years, 126 for consecutive three
years, 866 for consecutive 2 years. Although exact re-
sponse rate of the survey was not known, more than
90% of patients and all doctors answered the question-
naire. For each year, 60% of patients were recruited
from hospitals, while 20% were enrolled from respira-
tory clinics with the remaining 20% from general clin-
ics. Males and females comprised 43.8% and 55.6% of
the subjects, respectively (0.6% gave no answer). By
age, 12.2%, 17.1%, 13.7%, 14.8%, 17.9%, 19.3%, and 5.0%
were <29, 30-39, 40-49, 50-59, 60-69, 70-79 and 80
Survey of Patients with Bronchial Asthma
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Fig.　2　Changes in treatment over 5 years. The percentage of patients treated with ICS 
showed little change, while treatment with LABA and LTRA increased.
Inhaled
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Inhaled long acting
beta 2 agonists
Theophylline
Leukotriene
antagonists
(%)0 20 40 60 80 100
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Fig.　3　Changes in cases with controlled asthma based on 
the GINA classifi cation, using answers to the Tama original 
questionnaire. *p < 0.05 (χ2 test).
0 10 20 30 40 50
2002
2003
2004
2005
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(%)
*
% controlled
years old. The severity distribution was 33.5%, 33.8%,
22.8% and 7.4% in Steps 1, 2, 3 and 4, respectively,
with no significant change in this distribution over 5
years (Fig. 1). ICS were used in >80% of patients,
again with no significant change in this rate over the
5-year period. Use of LTRA and LABA increased and
that of theophylline decreased over 5 years (Fig. 2).
The percentage of patients with controlled asthma
based on the GINA classification was significantly
lower in 2006 than in 2002 (Fig. 3). No changes in the
incidence of symptoms, sleep disorder and distur-
bance in daily life were found over 5 years; however,
visits to an emergency room due to an asthma attack
decreased from 34.9% of patients in 2002 to 19.3% in
2006 (Fig. 4).
Multivariate analysis of patient background factors
was performed to identify factors with an association
with visits to an emergency room due to an asthma
attack. This analysis was performed using data
pooled over the 5 years of the study. Divergence be-
tween the asthma stage and the patient’s recognition
of severity was found to be significantly related to vis-
its to an emergency room. In other words, the risk for
a visit to an emergency room increased in patients
who considered their condition to be more severe
than their asthma stage as assessed by a physician
(Fig. 5).
To determine the cause of the reduction in fre-
quency of visits to an emergency room, effect of com-
bined therapy with ICS was evaluated. LTRA and
LABA were chosen for this analysis because use of
these agents as concomitant drugs increased over the
5-year study period. The backgrounds of 54 patients
in the ICS + LABA group and 45 patients in the ICS +
LTRA group are shown in Table 3. The mean ages
were 51.0 ± 20.0 years in the ICS + LABA group and
54.4 ± 18.1 years in the ICS + LTRA group. The sever-
ity distribution of patients in the ICS + LABA group
was 11 (20.4%), 24 (44.4%), 15 (27.8%) and 2 (3.7%) in
Steps 1, 2, 3 and 4, respectively, and for patients in
the ICS + LTRA group it was 12 (26.7%), 18 (40.0%),
12 (26.7%) and 2 (4.4%), respectively. The ICS doses
(converted to BDP) were 745 ± 351 and 680 ± 283 μg
day before and one year after initiation of combina-
tion therapy, respectively, in the ICS + LABA group.
The respective doses in the ICS + LTRA group were
657 ± 356 and 686 ± 319 μgday, with no significant
difference between groups. The percentages of pa-
tients who visited an emergency room due to an
asthma attack were 18.5% before and 22.2% in the first
year after initiation of combination therapy in the
ICS + LABA group, with no significant difference be-
tween these rates. In contrast, visits to an emergency
room due to an asthma attack significantly decreased
from 24.4% before to 6.6% in the first year after initia-
tion of combination therapy in the ICS + LTRA group
Ohshima N et al.
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Fig.　4　Changes over 5 years in asthma symptoms, sleep disorder, disturbance in daily life, and visits to an 
emergency room due to an asthma attack, based on answers to 4 questions on the Tama original questionnaire. 
a: Symptoms occurring twice or more/week (patients who answered “twice or more/week” and “almost every 
day”); b: Sleep disorder (patients who gave answers other than “I sleep well”); c: Disturbance of daily life (patients 
who gave answers other than “No”); and d: Frequency of visits to an emergency room due to an asthma attack 
(patients who gave answers other than “Never”). *p < 0.05 (χ2 test).
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(Fig. 6).
DISCUSSION
In this study, we followed patients with bronchial
asthma in Tama region, Tokyo, Japan for 5 years and
found that the frequency of visits to an emergency
room due to an asthma attack was reduced over time.
Although these data might have been collected in dif-
ferent group of patients, the severity of bronchial
asthma and the ICS dose were similar, which indi-
cates that the subjects had a similar treatment back-
ground. Since clinics and hospitals participating in
the survey were knowledgeable about current asthma
management, more than 80% of the patients were tak-
ing ICS throughout the survey period, which ex-
ceeded the average ICS usage (15% in 2005) in Japan.
This suggests that increased use of concomitant
drugs contributed to the reduction in visits to an
emergency room. Therefore, the effects of LTRA and
LABA on the frequency of visits to an emergency
room were evaluated. Our data indicated that a com-
bination of ICS and LTRA resulted in a significant de-
crease in the frequency of visits to an emergency
room in the one year after initiation of combination
treatment. These results demonstrate the efficacy of
LTRA for treatment of bronchial asthma. As for pa-
tients’ selection, we did not provide any selection cri-
teria whether to add LTRA or LABA to ICS to better
manage the particular patients. In fact, each doctor in-
dependently decided additional medication, resulting
in better QOL in LTRA + ICS group.
The Gaining Optimal Asthma control (GOAL)
study confirmed the efficacy of the combination of a
LABA (salmeterol) and an ICS (fluticasone propion-
ate, Flutide), but total control of asthma with
salmeterol-fluticasone propionate (SFC) therapy was
only achieved in 41% of patients.12 Bateman et al.
showed that patients treated with ICS and LABA in
combination had a lower risk for acute and severe de-
terioration of asthma compared to those treated with
ICS alone; however, no difference in asthma-related
hospitalization and death or the risk for asthma-
related endotracheal intubation was found between
the groups.13 Therefore, an increase in the rate of to-
tal control of asthma and decreased asthmatic death
requires a combination of an anti-inflammatory drug
with ICS.
LTRA are oral drugs that have a strong anti-
Survey of Patients with Bronchial Asthma
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Fig.　5　Multivariate analysis of background factors with a possible association with visits to an emergency room due to 
an asthmatic attack. The odds ratio ( ) and 95% confi dence interval (—) are shown.
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Table　3　Background of patients in the ICS + LABA and ICS + LTRA groups
ICS + LABA (n = 54) ICS + LTRA (n = 45)
Male/Female (number of patients) 25/29 20/25
Age (years) 51.0 ± 20.0 54.4 ± 18.1
Asthmatic stage (number of patients)
Step 1 11 12
Step 2 24 18
Step 3 15 12
Step 4  2  2
Dose of ICS (μg/day)
Before combination therapy 745 ± 351 657 ± 356
At 1 year after combined therapy 680 ± 283 686 ± 319
Data are shown as the number of patients or the mean ± SD.
inflammatory effect on the peripheral airway via sys-
temic delivery. The oral route of delivery gives good
compliance in elderly patients for whom inhalation is
difficult. The concept of a dual pathway of inflamma-
tion has been proposed: i.e., there are two kinds of
airway inflammation that are treatable and untreat-
able by ICS and LTRA has an inhibitory effect on in-
flammation that is untreatable by ICS.14 Airway infec-
tion is the major factor that induces a bronchial
asthma attack. Several studies have shown that treat-
ment with an LTRA for respiratory syncytial (RS) vi-
rus infection improved the severity of bronchiolitis
and inhibited exacerbation of asthma.15-17 This sug-
gests that LTRA have a strong effect on inflammation
Ohshima N et al.
480 Allergology International Vol 60, No4, 2011 www.jsaweb.jp
Fig.　6　Frequency of visits to an emergency room due to an asthmatic attack in groups treated with ICS and different 
concomitant drugs. a: ICS + LABA, b: ICS + LTRA. *p < 0.05 (Wilcoxon test).
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caused by viral infection. Allergic rhinitis, a common
complication of asthma, may also be involved in exac-
erbation of inflammation in the lower respiratory
tract, and LTRA may inhibit the actions of leukotriene
related to both diseases.18 The additional effects of
LTRA beyond those of treatment with ICS may be re-
sponsible for the reduction in emergency room visits.
Multivariate analysis showed that the frequency of
visits to an emergency room increased when there
was a gap of between the perception of doctors and
patients about medical conditions, especially in cases
where doctors under diagnosed the conditions.
Therefore, better control of asthma symptoms re-
quires improved treatment and promotion of
guideline-based evaluation and treatment. Programs
aimed at reducing the death rate from asthma have
been promoted for 10 years in Finland, and this strat-
egy is very commendable.6 In Japan, further educa-
tion is required to improve the understanding of
asthma as an inflammatory disease and to promote
the use of guidelines based on the relationship be-
tween primary care practitioners and specialists. The
increased percentage of patients under good asthma
control suggests that a survey on asthma conditions
for 5 years can improve the attitudes of specialists,
primary care physicians, and the patients themselves.
When most of the asthma patients use ICS, the im-
portance of additional drugs may be highlighted. In
this study, use of additional LTRA proved to be help-
ful to improve the QOL of asthma patients.
ACKNOWLEDGEMENTS
We would like to express our sincere gratitude for
the cooperation of all the physicians in the hospitals
and clinics that received the survey.
CONFLICT OF INTEREST
No potential conflict of interest was disclosed.
REFERENCES
1. Bousquet J, Michel FB. International consensus report on
diagnosis and management of asthma. Allergy 1992;47:
129-32.
2. [Annual population survey report from the Ministry of
Health, Labour and Welfare of Japan 2008] (in Japanese).
Available at: http:www.mhlw.go.jptoukeisaikinhwji
nkougepponengai08toukei6.html. Accessed June 3,
2009.
3. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola
AM. Asthma. From bronchoconstriction to airways in-
flammation and remodeling. Am J Respir Crit Care Med
2000;161:1720-45.
4. Sumi Y, Hamid Q. Airway remodeling in asthma. Allergol
Int 2007;56:341-8.
5. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-
dose inhaled corticosteroids and the prevention of death
from asthma. N Engl J Med 2000;343:332-6.
6. Haahtela T, Tuomisto LE, Pietinalho A et al. A 10 year
asthma programme in Finland: major change for the bet-
ter. Thorax 2006;61:663-70.
7. Adachi M, Ohta K, Morikawa A, Nishima S. [Asthma in-
sights & reality in Japan 2005]. Arerugi 2006;55:1340-3.
8. Nakazawa T, Dobashi K. Current asthma deaths among
adults in Japan. Allergol Int 2004;53:205-9.
9. Ministry of Health and Welfare, Japan. Asthma prevention
and management guidelines. Int Arch Allergy Immunol
2000;121 (Suppl 1):1-77.
10. Japanese Society of Allergology. [Asthma Prevention and
Management Guideline 2009, Japan]. Tokyo: Kyowa Ki-
kaku, 2009;92-113 (in Japanese).
11. Global Initiative for Asthma. Global Strategy for Asthma
Management and Prevention. Updated 2009. Available at:
http:www.ginasthma.org.
12. Bateman ED, Boushey HA, Bousquet J et al. Can
guideline-defined asthma control be achieved? The Gain-
ing Optimal Asthma ControL study. Am J Respir Crit Care
Med 2004;170:836-44.
13. Bateman E, Nelson H, Bousquet J et al. Meta-analysis: ef-
fects of adding salmeterol to inhaled corticosteroids on
serious asthma-related events. Ann Intern Med 2008;149:
33-42.
14. Peters-Golden M, Henderson WR Jr. Leukotrienes. N
Engl J Med 2007;357:1841-54.
15. Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast
reduces asthma exacerbations in 2- to 5-year-old children
with intermittent asthma. Am J Respir Crit Care Med 2005;
171:315-22.
Survey of Patients with Bronchial Asthma
Allergology International Vol 60, No4, 2011 www.jsaweb.jp 481
16. Johnston NW, Mandhane PJ, Dai J et al. Attenuation of
the September epidemic of asthma exacerbations in chil-
dren: a randomized, controlled trial of montelukast added
to usual therapy. Pediatrics 2007;120:e702-12.
17. Robertson CF, Price D, Henry R et al. Short-course mon-
telukast for intermittent asthma in children: a randomized
controlled trial. Am J Respir Crit Care Med 2007;175:323-
9.
18. Bjermer L. Time for a paradigm shift in asthma treatment:
from relieving bronchospasm to controlling systemic in-
flammation. J Allergy Clin Immunol 2007;120:1269-75.
